AI
Sunday, July 02, 2006 12:32:21 PM
That's the risk vrtx is running by keeping US rights and paying 50% of development costs.
Answer is we should know after the phase IIB
Efficacy is eye popping, tox on the other hand...tbd
I'm not invested in vrtx btw, too rich for me. I wouldn't be surprised if 950 blows up but I hope it works out, would be very cool and one of the few true biotech breakthrough drugs.
Answer is we should know after the phase IIB
Efficacy is eye popping, tox on the other hand...tbd I'm not invested in vrtx btw, too rich for me. I wouldn't be surprised if 950 blows up but I hope it works out, would be very cool and one of the few true biotech breakthrough drugs.
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
